Benzotriazole in Cancer: A Systematic Review on Preclinical Evidence and Structure–Activity Relationship
Open Access
- 30 December 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 77
Abstract
Background: A benzotriazole is a heterocycle frequently used in medicinal chemistry to obtain potent drug candidates, including anticancer agents. Nonetheless, the available literature lacks a comprehensive review of the in vitro and in vivo studies regarding these derivatives. Thus, our study aims to review the preclinical evidence on benzotriazole derivatives that showed potential as anticancer candidates, focusing on the cytotoxicity, mechanisms of action, structure–activity relationship, and methodological rigor of the included studies. Methods: We searched PubMed, Scopus, and Web of Science and included 41 studies in our analysis following the selection process. Additionally, we assessed the risk of bias using the QUIN tool for in vitro and the SYRCLE tool for in vivo studies in order to assess the methodological rigor of the included studies. Results: The benzotriazole derivatives were classified according to their structure in four classes, namely N-derivatives, C-derivatives, fused derivatives, and organometallic compounds. The in vitro results showed that certain derivatives, such as halogen, alkyl-aryl, or natural-base hybrids, can have superior cytotoxicity compared to parent molecules, exerted through multiple mechanisms, such as apoptosis and cell cycle arrest. Additionally, the in vivo analysis highlighted that benzotriazole derivatives can reduce tumor mass in a dose-dependent manner, with only a slight degree of hepatotoxicity reported in one case. However, histopathological data were generally absent or limited and based on a very limited number of in vivo studies. Conclusions: Overall, benzotriazole derivatives remain promising candidates for cancer treatment. However, limited mechanistic and toxicity data, as well as the moderate risk of bias identified across studies, may limit our assessment. Therefore, future studies should employ more rigorous methodologies and explore the underlying anticancer and toxicity mechanisms to fully assess the therapeutic potential of benzotriazole derivatives.Keywords
Funding Information
- “Victor Babes” University of Medicine and Pharmacy, Timisoara
This publication has 106 references indexed in Scilit:
- Mechanisms and treatment of opioid‐induced pruritus: Peripheral and central pathwaysEuropean journal of pain, 2023
- Benzotriazole scaffold: An overview of antiproliferative potential, mechanisms of action, and structure–activity relationshipsArchiv der Pharmazie, 2023
- Advances in synthesis and biological activities of benzotriazole analogues: A micro reviewJournal of Heterocyclic Chemistry, 2022
- Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applicationsJournal of Heterocyclic Chemistry, 2021
- Synthesis and anticancer activity of benzotriazole derivativesJournal of Heterocyclic Chemistry, 2019
- Discovery of NewS‐Glycosides andN‐Glycosides of Pyridine‐biphenyl System with Antiviral Activity and Induction of Apoptosis inMCF7 CellsJournal of Heterocyclic Chemistry, 2019
- Ki-67: more than a proliferation markerChromosoma, 2018
- Modification of carboxylated multiwall nanotubes with benzotriazole derivatives and study of their anticancer activitiesMedicinal Chemistry Research, 2013
- Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexesCancer Chemotherapy and Pharmacology, 2000
- Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administrationPsychopharmacology, 1984